CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease.
Alzheimer’s disease
acetylcholinesterase
cerebrospinal fluid (CSF)
choline acetyltransferase
galantamine
nicotinic binding sites
positron emission tomography (PET)
red blood cells (RBCs)
Journal
Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
06
2019
accepted:
19
09
2019
entrez:
5
11
2019
pubmed:
5
11
2019
medline:
5
11
2019
Statut:
epublish
Résumé
Alzheimer's disease (AD) is a progressive disease with early degeneration of the central cholinergic neurons. Currently, three of four AD drugs act by inhibiting the acetylcholine (ACh) degrading enzyme, acetylcholinesterase (AChE). Efficacy of these drugs depends on available amount of ACh, which is biosynthesized by choline acetyltransferase (ChAT). We investigated whether treatment with a cholinesterase-inhibitor, galantamine, alters the relative levels of AChE to ChAT in cerebrospinal fluid (CSF) and whether levels of these CSF biomarkers correlate with
Identifiants
pubmed: 31680850
doi: 10.3389/fnmol.2019.00239
pmc: PMC6798072
doi:
Types de publication
Journal Article
Langues
eng
Pagination
239Informations de copyright
Copyright © 2019 Karami, Eriksdotter, Kadir, Almkvist, Nordberg and Darreh-Shori.
Références
Alzheimers Dement. 2015 Nov;11(11):1316-28
pubmed: 25676388
BMJ. 1999 Mar 6;318(7184):633-8
pubmed: 10066203
Neurology. 2001 Aug 14;57(3):489-95
pubmed: 11502918
J Neural Transm (Vienna). 2006 Nov;113(11):1791-801
pubmed: 16868793
PLoS One. 2013 Jun 19;8(6):e65936
pubmed: 23840379
Neurology. 2000 Jun 27;54(12):2261-8
pubmed: 10881250
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1012-6
pubmed: 11792847
Neuropharmacology. 2004 Sep;47(4):558-71
pubmed: 15380373
J Neurosci Rural Pract. 2015 Jan;6(1):33-8
pubmed: 25552849
Neurobiol Aging. 2008 Aug;29(8):1204-17
pubmed: 17379359
J Alzheimers Dis. 2015;44(4):1039-62
pubmed: 25408210
Curr Alzheimer Res. 2009 Feb;6(1):4-14
pubmed: 19199870
Drug Saf. 1998 Dec;19(6):465-80
pubmed: 9880090
Curr Alzheimer Res. 2010 Feb;7(1):67-73
pubmed: 20205672
Arch Neurol. 1993 Aug;50(8):873-80
pubmed: 8352676
Drugs Aging. 2003;20(10):777-89
pubmed: 12875613
J Neurochem. 2004 Mar;88(5):1102-13
pubmed: 15009666
Alzheimer Dis Assoc Disord. 2000 Oct-Dec;14(4):216-27
pubmed: 11186600
Drugs Aging. 2009;26(3):231-9
pubmed: 19358618
Psychopharmacology (Berl). 2007 May;191(4):1005-14
pubmed: 17310387
Aging (Milano). 2001 Jun;13(3):247-54
pubmed: 11442306
J Int Neuropsychol Soc. 1999 Sep;5(6):502-9
pubmed: 10561930
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Neuron. 1999 Nov;24(3):687-700
pubmed: 10595519
Int J Dev Neurosci. 2004 Nov;22(7):545-9
pubmed: 15465284
Neurochem Res. 2000 Oct;25(9-10):1185-90
pubmed: 11059792
J Mol Neurosci. 2002 Jun;18(3):211-22
pubmed: 12059039
Arch Neurol. 2004 Feb;61(2):252-6
pubmed: 14967774
Int J Geriatr Psychiatry. 2004 Jul;19(7):624-33
pubmed: 15254918
Neurobiol Aging. 2008 Feb;29(2):168-84
pubmed: 17196712
J Pharmacol Exp Ther. 2006 Apr;317(1):30-6
pubmed: 16354790
Neurosci Lett. 2003 Apr 10;340(2):148-52
pubmed: 12668258
Neurology. 1999 Mar 10;52(4):691-9
pubmed: 10078712
Neurobiol Aging. 2011 Jul;32(7):1236-48
pubmed: 19713000
Neurology. 2000 Jun 27;54(12):2269-76
pubmed: 10881251
J Alzheimers Dis. 2014;39(2):423-40
pubmed: 24217282